BioSpace News Archive

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at The Virtual MedTech Conference taking place September 8 – October 23, 2020. The Solutions Showcase presentation ‘Data Driven Studies: Unified eClinical Platforms to Run Your Clinical Trials’ is available on-demand as of today, September 21, 2020, at 12:00 AM EDT. The session features Andrew Schachter, Axiom’s Fou

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commencement of a proposed underwritten public offering of 5,500,000 shares of its common shares. Certain existing shareholders expect t

Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutic

Amwell®, a national telehealth leader, today announced the closing of its upsized initial public offering of 47,405,555 shares of its Class A common stock at an initial offering price of $18.00 per share,

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone

Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside Ventures (“Morningside”), alongside existing shareholders including London based 24Haymarket.

Keith describes cancer stem cells as the key drivers to the growth and spread of cancer. He adds that getting these stem cells to dedifferentiate normally would heal the disease.

Investors include: Pontifax, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One, and existing investors. Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations. JERUSALEM--( BUSINESS WIRE )-- Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today

--Long-term effects of MIS-C on cardiac function will need further study, as myocardial injury could have implications for future sports participation-- [21-September-2020] PHILADELPHIA , Sept. 21, 2020 /PRNewswire/ -- Using sensitive parameters to assess cardiac function, researchers at Children’s Hospital of Philadelphia (CHOP) have found that cardiac involvemen